![](/img/cover-not-exists.png)
261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2
Marzo-Ortega, Helena, Sieper, Joachim, Kivitz, Alan, Blanco, Richardo, Cohen, Martin, Delicha, Eumorphia-Maria, Rohrer, Susanne, Richards, HannoVolume:
58
Language:
english
Journal:
Rheumatology
DOI:
10.1093/rheumatology/kez107.077
Date:
April, 2019
File:
PDF, 78 KB
english, 2019